(Q35810353)

English

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study

scientific article published on 11 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Marek Spaczyński

2

object named as

M Spaczynski

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

author name string

T Schwarz

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

A Kaufmann

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

J Wysocki

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

A Gałaj

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

K Schulze

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

P Suryakiran

7

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

F Thomas

8

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

D Descamps

9

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

publication date

11 September 2014

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

BJOG: an International Journal of Obstetrics and Gynaecology

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

122

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

107-118

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

In vivo mechanisms of vaccine-induced protection against HPV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Aging and immune function: molecular mechanisms to interventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Age-specific prevalence of infection with human papillomavirus in females: a global review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

HPV infections in adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

The epidemiology of human papillomavirus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

The causal relation between human papillomavirus and cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4489326

27 July 2018

Human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

The natural history of cervical HPV infection: unresolved issues

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Carcinogenicity of human papillomaviruses

1 reference

https://api.crossref.org/works/10.1111%2F1471-0528.13070

21 January 2018

Cervical cancer vaccination indications, efficacy, and side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human papillomavirus infection in adolescent and young women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/25208608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/1471-0528.13070

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35810353&oldid=1967583717"